Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab A/S    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 12/01 10:55:00 am
2359 DKK   -1.46%
11:51aGENMAB A/S : Investor Presentation - December 2020
PU
11/25NOVARTIS : Genmab Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Genmab A/S : has published its Articles of Association

10/15/2020 | 09:40am EST

Genmab A/S has published its Articles of Association dated October 07, 2020. The Articles of Association can be found on Genmab's website: https://ir.genmab.com/genmab-news

Contact:
Marisol Peron, Corporate Vice President, Communications & Investor Relations
T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:
Andrew Carlsen, Senior Director, Investor Relations
T: +45 3377 9558; E: acn@genmab.com


Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

www.genmab.com

CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Attachment

Disclaimer

Genmab A/S published this content on 15 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 October 2020 13:39:05 UTC


© Publicnow 2020
All news about GENMAB A/S
11:51aGENMAB A/S : Investor Presentation - December 2020
PU
11/25NOVARTIS : Genmab Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
11/24Genmab Announces Enapotamab Vedotin Update
GL
11/24GENMAB A/S : Mereo BioPharma Group plc - Mereo BioPharma Appoints Suba Krishnan,..
AQ
11/20IMMUNOPRECISE ANTIBODIES : and Genmab Enter into a Technology Partnership Target..
AQ
11/13GENMAB A/S : 2020 Virtual Capital Markets Day – November 13, 2020
PU
11/11GENMAB A/S : Articles of association dated November 10, 2020 – English
PU
11/11NOVARTIS : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
More news
Financials
Sales 2020 9 832 M 1 592 M 1 592 M
Net income 2020 4 689 M 759 M 759 M
Net cash 2020 15 041 M 2 435 M 2 435 M
P/E ratio 2020 32,6x
Yield 2020 -
Capitalization 154 B 24 694 M 24 904 M
EV / Sales 2020 14,1x
EV / Sales 2021 17,1x
Nbr of Employees 712
Free-Float 95,2%
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 2 194,34 DKK
Last Close Price 2 352,00 DKK
Spread / Highest target 27,6%
Spread / Average Target -6,70%
Spread / Lowest Target -90,3%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Deirdre P. Connelly Chairman
Anthony Mancini Chief Operating Officer & Executive Vice President
Anthony Pagano Chief Financial Officer & Executive Vice President
Michael K. Bauer SVP, Head-Operations, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB A/S61.59%25 135
GILEAD SCIENCES, INC.-6.63%76 052
VERTEX PHARMACEUTICALS4.02%59 224
REGENERON PHARMACEUTICALS37.43%54 464
WUXI APPTEC CO., LTD.57.04%38 135
BIONTECH SE266.71%29 915